Thompson Davis & Co’s NeuroMetrix, Inc. Common Stock NURO Stock Holding History

Thompson Davis & Co’s Portfolio NURO Stock Details NURO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$52K	Sell	492 -438	-47%	-$44.5K	0.11%	194
2018 Q2	$97K	Sell	930 -203	-18%	-$22.4K	0.23%	106
2018 Q1	$128K	Buy	1,133 +604	+114%	+$75.7K	0.34%	72
2017 Q4	$73K	Buy	+529	New	+$76K	0.17%	134
2015 Q1	–	Sell	-18	Closed	-$92K	–	1280
2014 Q4	$92K	Buy	+18	New	+$78.9K	0.11%	190
2014 Q3	–	Sell	-15	Closed	-$72K	–	1253
2014 Q2	$72K	Buy	+15	New	+$76.1K	0.1%	216
2014 Q1	–	Sell	-7	Closed	-$56K	–	869
2013 Q4	$56K	Buy	+7	New	+$39.3K	0.08%	229

Other funds holding NURO

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NSIM

North Star Investment Management Chicago, Illinois $1.84B AUM 28.81% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFS

Orrstown Financial Services Harrisburg, Pennsylvania $674M AUM 23.23% 1-Year Est. Return

Randolph Company Cincinnati, Ohio $1.19B AUM 38.92% 1-Year Est. Return

Thompson Davis & Co's NURO Position: Q3 2018 in Review

Thompson Davis & Co reduced its NeuroMetrix, Inc. Common Stock (NURO) stake by 47% in Q3 2018, selling an estimated $44.5K and leaving 492 shares worth $52K. The position accounts for 0.11% of the portfolio, ranked #194.

Thompson Davis & Co first reported a position in NURO in Q4 2013 and has held it in 7 quarters since. The position peaked at $128K in Q1 2018. 13 funds tracked by Wall St. Rank hold NURO as of Q3 2018.

Thompson Davis & Co held 492 shares of NeuroMetrix, Inc. Common Stock worth $52K as of Q3 2018.
Thompson Davis & Co sold 438 NeuroMetrix, Inc. Common Stock shares in Q3 2018, an estimated $44.5K.
NeuroMetrix, Inc. Common Stock made up 0.11% of Thompson Davis & Co's portfolio in Q3 2018, its #194 holding.
Thompson Davis & Co first reported a position in NeuroMetrix, Inc. Common Stock in Q4 2013 and has held it in 7 quarters since.
Thompson Davis & Co's NeuroMetrix, Inc. Common Stock position peaked at $128K in Q1 2018.
13 funds tracked by Wall St. Rank held NeuroMetrix, Inc. Common Stock as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.